-
Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field
•
Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy (CGT), have entered into a long-term strategic alliance. Financial terms of the partnership were not disclosed. Partnership DetailsThe alliance aims to leverage Cell Store’s…
-
InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum
•
Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results for its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib in relapsing-remitting multiple sclerosis (RRMS) at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Study HighlightsThe data demonstrated significant efficacy of…
-
Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug HRS-1301 has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of hyperlipidemia. Clinical Approval DetailsThe approval marks a significant milestone for HRS-1301, a novel drug designed to address hyperlipidemia.…
-
Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow Pharmaceutical Co., Ltd, has received marketing approval from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) for its Enoparin (enoxaparin) product. The approved specifications include 0.2ml: 20mg, 0.4ml: 40mg, 0.6ml: 60mg, and 0.8ml:…
-
Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment
•
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare Medical Technology Co., Ltd, has received market approval from the National Medical Products Administration (NMPA) for its multipole renal arterial radiofrequency ablation system, Iberis. The device is approved as an adjuvant therapy for refractory hypertension…
-
Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its tenapanor, an innovative phosphate absorption inhibitor, in China. The drug, commercially known as Wan Ti Le, is now available for controlling serum phosphorus levels…
-
WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (HKG: 2359, SHA: 603259), has signed an expanded Memorandum of Understanding (MOU) with South Korea’s LigaChem Biosciences, Inc. to accelerate the development of next-generation antibody drug conjugates (ADCs).…
-
Kexing Biopharm and Bio-Sincerity Pharmaceutical Form Strategic Alliance
•
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE: 301096) have entered into a strategic partnership to collaborate on innovative drug development and overseas commercialization. Partnership DetailsThe alliance aims to leverage the strengths of both companies in drug development and commercialization. The partnership will…
-
Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy
•
China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed partner to advance the development of HAT001/HBM9013, a novel corticotropin releasing hormone (CRH) targeted therapy. The alliance aims to promote the drug’s development globally, excluding Greater China. Agreement DetailsUnder the agreement, the partner will hold…
-
Basecare and Rhea Labs Form Five-Year Alliance to Expand IVF Markets Globally
•
China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has entered into a five-year strategic alliance with Singapore’s Rhea Labs Pte. Ltd to jointly expand in vitro fertilization (IVF) markets globally. The partnership aims to leverage both companies’ commercial strengths in the US, Europe, South America, and Southeast Asia,…
-
Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates
•
Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences, Inc. to discover new small molecule drug candidates for immunology and neurology using BridGene’s chemical proteomics platform, IMTAC. The collaboration aims to advance projects through hit finding and early lead development, with Takeda holding exclusive…
-
Hansoh Pharmaceutical’s HS-10561 Receives NMPA Clearance for Chronic Spontaneous Urticaria
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug HS-10561, a Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of chronic spontaneous urticaria (CSU). Licensing AgreementHS-10561 was licensed from fellow Chinese…
-
J&J MedTech Launches Locally Produced HARMONIC 7s Scalpel in China
•
Johnson & Johnson MedTech, a US-based healthcare giant, announced the official launch of its HARMONIC 7s ultrasonic scalpel instrument in China, marking a milestone with local production at its Suzhou plant. Product HighlightsThe HARMONIC 7s features an innovative built-in intelligent chip and proprietary next-generation adaptive tissue algorithm (ATT), enabling continuous…
-
Thermo Fisher to Acquire Solventum’s Purification Business for USD 4.1B
•
Thermo Fisher Scientific (NYSE: TMO) has agreed to acquire Solventum’s (NYSE: SOLV) Purification & Filtration business for approximately USD 4.1 billion in cash, expanding its capabilities in biologics production and industrial filtration. Business ProfileSolventum’s unit is a global leader in purification and filtration technologies, serving biologics manufacturing, medical tech, and…
-
J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment
•
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval from China’s National Medical Products Administration (NMPA) for treating moderate to severe active Crohn’s disease (CD) in adults who have not responded adequately to traditional therapies or biologics. Drug ProfileTremfya, an interleukin-23 monoclonal antibody, was…
-
Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy
•
Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new indication for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adult patients with newly diagnosed multiple myeloma (NDMM). This marks the fourth treatment regimen approved for Sarclisa in…
-
YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial
•
YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive results from an investigator-initiated trial (ITT) of YOLT-203 in patients with primary hyperoxaluria type 1 (PH1). The therapy marks the first in vivo gene-editing treatment to demonstrate positive clinical data for PH1, showing excellent safety…
-
HQ Pharma and Shanghai Pharmaceuticals Expand Collaboration for Global Market Access
•
China’s HQ Pharma (Shanghai) Co., Ltd has entered into a new collaboration agreement with Shanghai Pharmaceutical Import & Export Co., Ltd., a wholly owned subsidiary of Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607). This partnership builds on their existing agreement from December 2023, aiming to enhance the international market access…
-
Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives
•
China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have entered into a strategic partnership to collaborate on the screening, diagnosis, and early intervention of Alzheimer’s disease (AD). Collaboration GoalsThe partnership will leverage the strengths of both companies to: Strategic SynergiesBy combining their expertise, Green…
-
Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review
•
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab) for review. The application seeks approval for Keytruda’s use in patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC)…
